Drug updated on 4/18/2024
| Dosage Form | Injection (intravenous; 1 mg/mL, 30 mg/30 mL [1 mg/mL] single-dose vials) |
| Drug Class | CD20-directed CD3 T-cell engagers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Summary
- Mosunetuzumab-axgb (Lunsumio) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. It has a better tolerability profile compared to PI3K inhibitors, evidenced by fewer discontinuations due to adverse events.
- Two studies provided insights into Lunsumio's safety and effectiveness in comparison with other treatments such as Tazemetostat, PI3K inhibitors, CART therapies, and anti-CD20 antibody-based regimens.
- Findings suggest that mosunetuzumab may present fewer safety concerns than intense CART therapies. However, direct comparisons are limited due to differences in study design.
- In terms of effectiveness, mosunetuzumab demonstrates superior outcomes over Tazemetostat in EHZ2 wild-type patients and over PI3K inhibitors for complete response (CR) and objective response rate (ORR). Comparisons slightly favored CART therapies over Mosunetuzumab for progression-free survival, but data supporting this is not straightforward.
- When compared with real-world data cohorts, significantly higher overall response rates (ORR) and complete response rates (CR) were observed in the Mosunetuzumab cohort, suggesting it could offer a meaningful clinical benefit over conventional third-line treatments.
- The documented effectiveness of mosunetuzumab in EHZ2 wild-type patients highlights its potential benefits within specific genetic subgroups while also demonstrating its efficacy outside controlled clinical trial environments.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Lunsumio (mosunetuzumab-axgb) Prescribing Information. | 2022 | Genetech Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. | 2024 | Clinical Lymphoma, Myeloma & Leukemia |
| Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy. | 2023 | Leukemia & Lymphoma |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Bispecific antibodies as monotherapy or in combinations for hematological malignancies: Latest updates from the EHA 2023 annual meeting. | 2023 | Expert opinion on biological therapy |
| NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023 | 2023 | National Comprehensive Cancer Network |